Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Published:2020-09-08 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Hu Huabin,She Longjiang,Liao Mengting,Shi Yin,Yao Linli,Ding Dong,Zhu Youwen,Zeng Shan,Carbone David P.,Huang Jin

Funder

Natural Science Foundation of Hunan Province

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference51 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin.,2018

2. Integrative bioinformatics analysis reveals potential long non-coding rna biomarkers and analysis of function in non-smoking females with lung cancer;Qiao;Med Sci Monit.,2018

3. Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients;Zou;Cancer Chemother Pharmacol.,2016

4. Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes;Zhou;Mol Med Rep.,2017

5. Cancer treatment and survivorship statistics, 2019;Miller;CA Cancer J Clin.,2019

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time-dependent efficacy analysis of first-line immunotherapies for advanced non–small cell lung cancer;BMC Cancer;2024-06-05

2. EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer;Advanced Science;2024-03-22

3. Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review;BMC Cancer;2024-03-06

4. Molecular characteristics and multivariate survival analysis of 43 patients with locally advanced or metastatic esophageal squamous cell carcinoma;Journal of Thoracic Disease;2024-03

5. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review;Cancers;2024-02-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3